CJC-1295 with or without DAC: pulse versus continuous

TL;DR

• DAC binds CJC-1295 to albumin, stretching its half-life to roughly 6–8 days and producing a continuous, low-grade elevation - the "GH bleed".
• Without DAC (mod GRF 1-29) it clears in about 30 minutes, producing a short pulse much closer to natural release.
• **Physiology is pulsatile, so continuous elevation is the non-physiologic option** - not the upgrade the convenience pitch implies.
• Both forms raise IGF-1, the axis's central safety concern - which is why baseline IGF-1 and age-appropriate cancer screening come before either.
• CJC-1295 is investigational and not FDA-approved in either form.
• Ipamorelin is the usual pairing because it was characterised as raising GH with minimal prolactin, cortisol or ACTH spillover (Raun et al., 1998).

Educational content, not medical advice. CJC-1295 is investigational and not FDA-approved. No doses, reconstitution math, or protocols appear - those belong with a physician. The GH/IGF-1 axis carries a cancer-screening requirement covered below.

---

CJC-1295 is a GHRH analogue - a signal that prompts your pituitary to release growth hormone - and it comes in two forms that behave very differently. With DAC (a Drug Affinity Complex that binds it to albumin), it lingers for days, producing a continuous, low-grade elevation of GH and IGF-1 often called a "GH bleed." Without DAC (the modified GRF 1-29 form), it clears in roughly half an hour, producing a short pulse that more closely mimics how your body naturally releases GH. The honest framing: the pulsatile (no-DAC) form is generally favoured because physiology is pulsatile - continuous elevation is the non-physiologic option, not the upgrade it sounds like - and both forms raise IGF-1, which is why the whole GH axis sits behind a cancer-screening gate. Here's the real comparison.

DAC vs no-DAC at a glance

Why pulsatile is the point

Your body doesn't pour out growth hormone steadily - it releases it in pulses, mostly at night, with low levels in between. That rhythm appears to matter: the troughs between pulses are part of how the system stays responsive. A continuous elevation (what DAC produces) overrides that rhythm, and the theoretical concerns are that it may blunt the natural pattern and push IGF-1 up persistently rather than in physiologic waves. So the no-DAC form's faster clearance is a feature, not a flaw - it nudges the pituitary and then gets out of the way, leaving the body's own pulsatility more intact. "Lasts longer" reads as better only if you assume more-continuous-exposure is the goal; for the GH axis, it generally isn't.

Why it's usually paired with a GHRP like ipamorelin

CJC-1295 (the GHRH side) is frequently discussed alongside ipamorelin (a GHRP - a different class that also prompts GH release, via the ghrelin receptor). The rationale is that the two act through complementary mechanisms. Ipamorelin's appeal is selectivity: unlike older GHRPs (GHRP-2, GHRP-6, hexarelin), it was characterised as raising GH with minimal spillover into prolactin, cortisol or ACTH (Raun et al., 1998). That's a mechanistic rationale, not a recipe - the specifics of any such pairing are a clinical decision, not something to assemble from a forum post. (Ipamorelin compound reference.)

The safety question both forms share

This is the part the "which version" debate often skips: both DAC and no-DAC raise IGF-1, and a persistently elevated IGF-1 is the axis's central safety concern. Higher circulating IGF-1 has been associated with risk of certain cancers (Renehan et al., Lancet 2004), which is why responsible use of anything that drives the GH/IGF-1 axis starts with screening - baseline IGF-1, and age-appropriate cancer screening - before therapy, and monitoring during. The DAC-vs-no-DAC choice is downstream of that gate, not a substitute for it. (The full picture is in growth hormone and cancer risk and the GH axis explained.)

The honest bottom line - and where to start

Between the two: the no-DAC (pulsatile) form is generally preferred because it respects the body's natural GH rhythm, while the DAC form's multi-day "bleed" trades that physiology for fewer administrations - a trade most clinical reasoning doesn't favour. But the more important point sits above the choice entirely: CJC-1295 is investigational, raises IGF-1, and belongs behind cancer screening and physician monitoring - not behind a vendor's convenience pitch. If the GH axis is something you're exploring, the first step is the screening and the supervision, not picking a half-life.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore CJC-1295.

Frequently asked questions

What's the difference between CJC-1295 with and without DAC? DAC binds the peptide to albumin so it lasts ~6–8 days, giving continuous GH elevation (a "GH bleed"). Without DAC (mod GRF 1-29) it clears in ~30 minutes, giving a short pulse that better mimics natural GH release.

Is CJC-1295 with or without DAC better? The no-DAC pulsatile form is generally preferred because the body's own GH release is pulsatile, and continuous elevation is the non-physiologic option. But both raise IGF-1 and both are investigational - the bigger question is screening and supervision, not half-life.

Is CJC-1295 safe? It's investigational and not FDA-approved, and like anything that drives the GH/IGF-1 axis it raises IGF-1 - which carries cancer-screening considerations. Responsible use means baseline screening and physician monitoring, not self-administration.

Related reading

• The GH axis explained · growth hormone and cancer risk · Tesamorelin - the FDA-approved GHRH analogue
• Part of The Complete Guide to Peptides

---

Educational content, not medical advice. CJC-1295 is investigational and not FDA-approved. The GH/IGF-1 axis carries cancer-screening requirements; any use is physician-directed with monitoring. No doses or protocols are provided. Claims for the Malaysian market are subject to MAB requirements.

References

• Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91:799–805 (PMID 16352683). · Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552–561 (PMID 9849822). · Renehan AG, et al. IGF-1, IGF binding protein-3, and cancer risk: systematic review and meta-regression. Lancet. 2004;363:1346–1353.